Nanologica AB (publ) announces that Nasdaq Stockholm’s Listing Committee has approved the company’s application for admission to trading of the company’s shares on Nasdaq Stockholm’s main market. The approval is conditioned upon customary conditions being fulfilled, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority.
The first day of trading on Nasdaq Stockholm’s main market is scheduled for Tuesday 29 March 2022 and the last day of trading on Spotlight Stock Market is scheduled for Monday 28 March 2022. The shares will be traded under the same ticker (NICA) and ISIN-code (SE0005454873). There is no offering or issue of new shares in connection with the list change, and shareholders in Nanologica do not need to take any actions.
Nanologica’s board of directors and management see the listing as an important step in Nanologica’s continued development and growth. The company regards the list change as a natural step that reflects the maturity of its business from a capital market perspective, by making the share more widely available to both Swedish and foreign institutional investors. The listing also entails a seal of quality for Nanologica and the development the company is pursuing.
”I have had the privilege of leading and developing Nanologica for the past 11 years and it is with both pride and humbleness that we are now taking this step. By listing the share on Nasdaq Stockholm, we are given increased exposure and the opportunity to attract institutional and international investors to a greater extent. With the highly qualified management team we have in place and with an imminent product launch on a broad front, we are ready to step up the business to completely new levels.”, Nanologica’s CEO Andreas Bhagwani comments.
For further information, please refer to the prospectus that has been prepared due to the listing and is expected to be approved and registered by the Swedish Financial Supervisory Authority and published on the company’s website well in advance of the first day of trading on Nasdaq Stockholm’s main market.
Advokatfirman Lindahl has acted as legal advisor in connection with the listing on Nasdaq Stockholm.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: firstname.lastname@example.org
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases. In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje and the company’s share (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.